Arvinder K. Dhalla
Papers
8
Total Citations
110
H-Index
3
About
Arvinder K. Dhalla is a pioneering researcher in the field of oral biotherapeutic delivery, specializing in the development of an innovative robotic pill platform that promises to transform the administration of injectable medications. Her major contributions center on engineering an orally ingestible robotic pill capable of safely and reliably delivering large-molecule drugs—such as antibodies, peptides, and hormones—directly through the intestinal wall, achieving high systemic bioavailability comparable to traditional injections. This breakthrough addresses a critical unmet need, as chronic injections for conditions like osteoporosis, diabetes, and autoimmune diseases often lead to poor patient compliance due to pain and inconvenience. Dhalla’s most cited work, a 2021 study on the robotic pill’s safety and tolerability in healthy subjects (94 citations), established foundational clinical evidence. Subsequent phase 1 trials demonstrated successful delivery of teriparatide for osteoporosis and an ustekinumab biosimilar, with bioavailability rivaling subcutaneous administration. Her research has also explored oral delivery of GLP-1 agonists and follicle-stimulating hormone, showcasing the platform’s versatility. By enabling painless, oral administration of biotherapeutics, Dhalla’s work holds profound implications for improving patient adherence and quality of life, positioning her at the forefront of a paradigm shift in drug delivery.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8